正在研究的用于治疗 2 型糖尿病的酪氨酸激酶抑制剂。
Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes.
机构信息
a Department of Internal Medicine, Division of Endocrinology, Diabetes, and Nutrition , University of Maryland School of Medicine , Baltimore , MD , USA.
b Department of Medicine , University of Maryland School of Medicine, Physician-in-Chief, University of Maryland Medical Center , Baltimore , MD , USA.
出版信息
Expert Opin Investig Drugs. 2016;25(3):287-96. doi: 10.1517/13543784.2016.1142531. Epub 2016 Feb 4.
INTRODUCTION
Type 2 diabetes is characterized by hyperglycemia that is the result of β-cell failure in the setting of peripheral insulin resistance. It is estimated that greater than 300 million individuals worldwide have diabetes. Tyrosine kinase inhibitors (TKIs), which are used to treat a variety of cancers, appear to have antihyperglycemic effects.
AREAS COVERED
This review summarizes studies that have investigated the use of TKIs in animal models of diabetes. Additionally, the authors review case series describing the effects of TKIs on glucose levels in adults taking these drugs for FDA approved indications.
EXPERT OPINION
Given the scope and size of the worldwide diabetes epidemic, reports of amelioration or possible cure of the disease warrant special attention. TKIs appear to lower glucose levels in some, but not all individuals. Multi-center prospective studies are needed in which patient with diabetes treated with TKI undergo phenotyping to identify responders versus non responders to allow for precision medicine.
简介
2 型糖尿病的特征是高血糖，这是外周胰岛素抵抗情况下β细胞功能衰竭的结果。据估计，全球有超过 3 亿人患有糖尿病。酪氨酸激酶抑制剂（TKIs）被用于治疗多种癌症，它们似乎具有降血糖作用。
涵盖领域
本综述总结了研究 TKIs 在糖尿病动物模型中的应用。此外，作者还回顾了描述 TKI 对接受这些药物治疗 FDA 批准适应症的成年人血糖水平影响的病例系列。
专家意见
鉴于全球糖尿病流行的范围和规模，关于改善或可能治愈该疾病的报告值得特别关注。TKIs 似乎可以降低一些但不是所有个体的血糖水平。需要进行多中心前瞻性研究，对接受 TKI 治疗的糖尿病患者进行表型分析，以确定对药物有反应的患者和无反应的患者，从而实现精准医疗。
Zotero 插件